Тромбоцитопения и COVID-19 – предизвикателството все още остава

Ваня Славчева Попова

doi:10.36865/2023.v14i1.176

Ваня Славчева Попова

DOI: https://doi.org/10.36865/2023.v14i1.176

Keywords: тромбоцитопения, COVID-19, прогноза

Abstract

Бързото разпространение на COVID-19, както и критичният брой на смъртните случаи в световен мащаб наложиха необходимостта за кратко време да се предприемат ефективни мерки за ограничаване разпространението на заболяването, изграждане на диагностично терапевтичен алгоритъм и мерки, свързани с превенция на болестта. Към днешни дни е общоприето становището за системния характер на заболяването, като в немалка част от наличните доклади са представени данни за ангажиране на хемопоезата.

Целта на настоящия преглед е на базата на публикувани доклади за периода след 2019 г. да се направи обзор върху възможните патогенетични механизми, водещи до развитие на тромбоцитопения при пациенти с доказан COVID-19.

References

Slavcheva V. Treatment of chronic lymphocytic leukemia during COVID-19. Hematology. 2022; 58(1-2):19-24.
Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020 May;27(5):1451-1454.
Mohammed RN, Tamjidifar R, Rahman HS, et al. Correction: A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19). Cell Commun Signal. 2022 Sep 8;20(1):139. Erratum for: Cell Commun Signal. 2022 Jun 2;20(1):79.
Fara A, Mitrev Z, Rosalia RA, et al. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biol. 2020 Sep;10(9):200160.
Mangalmurti N, Hunter CA. Cytokine Storms: Understanding COVID-19. Immunity. 2020 Jul 14;53(1):19-25.
Morgulchik N, Athanasopoulou F, Chu E, et al. Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm. Interface Focus. 2021 Dec 10;12(1):20210006.
Zhang Y, Zeng X, Jiao Y, et al. Mechanisms involved in the development of thrombocytopenia in patients with COVID-19. Thromb Res. 2020 Sep;193:110-115.
Lefrançais E, Ortiz-Muñoz G, Caudrillier A, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017 Apr 6;544(7648):105-109.
Johnston I, Hayes V, Poncz M. Threading an elephant through the eye of a needle: Where are platelets made? Cell Res. 2017 Sep;27(9):1079-1080.
Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020 Jun;99(6):1205-1208.
Rohlfing AK, Rath D, Geisler T, et al. Platelets and COVID-19. Hamostaseologie. 2021 Oct;41(5):379-385.
Conway EM, Mackman N, Warren RQ, et al. Understanding COVID-19-associated coagulopathy. Nat Rev Immunol. 2022 Oct;22(10):639-649.
Campbell RA, Boilard E, Rondina MT. Is there a role for the ACE2 receptor in SARS-CoV-2 interactions with platelets? J Thromb Haemost. 2021 Jan;19(1):46-50.
Barrett TJ, Bilaloglu S, Cornwell M, et al. Platelets contribute to disease severity in COVID-19. J Thromb Haemost. 2021 Dec;19(12):3139-3153.
Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-1026.
Bobircă A, Bobircă F, Ancuța I, et al. COVID-19-A Trigger Factor for Severe Immune-Mediated Thrombocytopenia in Active Rheumatoid Arthritis. Life (Basel). 2022 Jan 6;12(1):77.
Ravi S, Khadka S, Raghu CS, et al. COVID-19 Presenting With a Challenging Combination of Thrombocytopenia and Thrombosis. J Med Cases. 2022 Apr;13(4):168-171.